30,000 volunteers - and counting!

Posted:
17
September 2004

Today we are celebrating after successfully recruiting our 30,000th clinical trial volunteer. This major milestone has been reached in just two and a half years, demonstrating that we continue to lead the market in volunteer recruitment.Wendy Galloway, head of Volunteer Recruitment, commented: “We are all delighted to have recruited 30,000 volunteers in such a short period of time, and I would like to thank everyone within our dedicated volunteer recruitment team for making this possible. I would also like to thank the hundreds of volunteers who participate in our trials every month — we appreciate that their full co-operation is pivotal to any study, which is why we make the time they spend staying in our wards as safe, comfortable and enjoyable as possible.”Our highly motivated volunteer recruitment team consistently recruits over 1,000 volunteers a month. We have an integrated sales and marketing approach to recruitment, including targeted advertising campaigns and our dedicated recruitment website www.trials4us.co.uk.Due to the increasing number of studies conducted by Richmond, the volunteer recruitment team is constantly building upon our impressive volunteer database to ensure that all study recruitment targets are met. The database encompasses a wide range of populations, for instance 14% of the database are healthy volunteers aged 60 years or above. We guarantee volunteer panels for all our clients. For more information visit our volunteer recruitment section.

Trials4us

Latest news

Upcoming Event

The 41st Annual Scientific Meeting of the Japanese Society of Clinical Pharmacology and Therapeutics (JSCPT)

4 – 5 December 2020
The 41st Annual Scientific meeting focuses on international collaboration in the pursuit of drug discovery and drug development.
View event

Contributing to our community in 2020

December 17, 2020
Richmond Pharmacology has a long-standing tradition of supporting local, national, and international charities and 2020 is no exception.
Read more

Richmond Pharmacology supports Cardior Pharmaceuticals with the pioneering trial of an oligonucleotide-based drug in heart failure patients

December 14, 2020
Richmond Pharmacology is delighted to welcome the positive Phase Ib results of Cardior Pharmaceuticals lead compound CDR132L for heart failure.
Read more

Marking a milestone for gene editing

November 10, 2020
We are pleased to share that Richmond Pharmacology, in partnership with Intellia Therapeutics and the Royal Free Hospital, have treated the first patient in a landmark CRISPR/Cas9 clinical trial of NTLA-2001
Read more